Human Umbilical Cord Mesenchymal Stem Cell Therapy for Atopic Dermatitis Through Inhibition of Neutrophil Chemotaxis

    May 2025 in “ Stem Cell Research & Therapy ”
    Jinjin Shao, Zhiqi Xie, Zhichao Ye, Guoyu Chen, Yiru Wang, Lili Zhang, Fang Liu, Siming Zhang, Xiaobo Lin, Jiahong Wang, Ying Chen, Yunxiang Chen, Xin Pan, Feifei Wu, Ruolang Pan, Jinfeng Liang, Lijiang Zhang
    Studysummary In this study, human umbilical cord mesenchymal stem cells and their conditioned medium significantly improved symptoms in mouse models of atopic dermatitis, potentially through exosome-dependent pathways, suggesting a cell-free therapeutic strategy.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This study explores the use of human umbilical cord mesenchymal stem cells (hUC-MSCs) and their conditioned medium (hUC-MSC-CM) for treating atopic dermatitis (AD) in mouse models. Both treatments significantly alleviate AD-like symptoms, such as erythema and epidermal thickening, by inhibiting neutrophil chemotaxis and regulating chemokine expression through the STAT3 signaling pathway. The hUC-MSC-CM offers a promising cell-free alternative to whole-cell therapy, suggesting a new strategy for AD treatment. The study supports further research and potential clinical trials for using hUC-MSCs in managing moderate-to-severe AD.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results